Back to News
Market Impact: 0.2
Q32 Bio Appoints New CMO And CDO To Support Advancement Of Bempikibart
Source: Nasdaq
Healthcare & BiotechManagement & GovernanceCompany Fundamentals
Q32 Bio appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. The leadership additions are intended to support advancement of the company’s lead program, Bempikibart, into its next stage of development; the provided article text does not specify the stage or timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
QTTB0.40
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Microsoft's Big Bets on AI Start to Pay Off
- Google's Gemini 4 Carbon looks like a diamond in the rough